CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03546361 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
BIOLOGICAL: Pembrolizumab

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]